These patients were randomly assigned ( 1:1 ) to receive either cisplatin plus gemcitabine ( cisplatin 75 mg/m ( 2 ) on day 1 and gemcitabine 1250 mg/m ( 2 ) on days 1 and 8 ) or paclitaxel plus gemcitabine ( paclitaxel 175 mg/m ( 2 ) on day 1 and gemcitabine 1250 mg/m ( 2 ) on days 1 and 8 ) given intravenously every 3 weeks for a maximum of eight cycles .